Anne-Marie Koop

174 REFERENCES 1. Wolferen SA Van, Marcus JT, Boonstra A, Marques KMJ, Bronzwaer JGF, Spreeuwenberg MD, Postmus PE, Vonk-Noordegraaf A. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007;28:1250–1257. 2. Norozi K, Wessel A, Alpers V, Arnhold JO, Geyer S, Zoege M, Buchhorn R. Incidence and Risk Distribution of Heart Failure in Adolescents and AdultsWith Congenital Heart Disease After Cardiac Surgery. Am J Cardiol 2006;97:1238–1243. 3. Vonk Noordegraaf A, Westerhof BE, Westerhof N. The Relationship Between the Right Ventricle and its Load in Pulmonary Hypertension. J Am Coll Cardiol 2017; 69 :236–243. 4. Borgdorff MAJ, Koop AMC, Bloks VW, Dickinson MG, Steendijk P, Sillje HHW, Wiechen MPH van, Berger RMF, Bartelds B. Clinical symptoms of right ventricular failure in experimental chronic pressure load are associated with progressive diastolic dysfunction. J Mol Cell Cardiol Elsevier Ltd; 2015;79:244–253. 5. Ryan JJ, Archer SL. The right ventricle in pulmonary arterial hypertension: Disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res S.L. Archer, Department of Medicine, Queen’s University, Kingston, ON K7L 3N6, Canada; 2014;115:176–188. 6. Borgdorff MAJ, Dickinson MG, Berger RMF, Bartelds B. Right ventricular failure due to chronic pressure load: What have we learned in animal models since the NIH working group statement? Heart Fail Rev M.A.J. Borgdorff, Department of Pediatric Cardiology, Center for Congenital Heart Diseases, Beatrix Children’s Hospital, University Medical Center Groningen, Groningen, Netherlands; 2015;20:475–491. 7. RocheSL,RedingtonAN.Rightventricle:Wrongtargets?Anotherblowforpharmacotherapy in congenital heart diseases. Circulatio n 2013;127:314–316. 8. Borgdorff MA, Bartelds B, Dickinson MG, Steendijk P, Berger RMF. A cornerstone of heart failure treatment is not effective in experimental right ventricular failure. Int J Cardiol Elsevier Ireland Ltd; 2013;169:183–189. 9. Bom T Van Der, Winter MM, Bouma BJ, Groenink M, Vliegen HW, Pieper PG, Dijk APJ Van, Sieswerda GT, Roos-Hesselink JW, Zwinderman AH, Mulder BJM. Effect of valsartan on systemic right ventricular function: A double-blind, randomized, placebo-controlled pilot trial. Circulation 2013;127:322–330. 10. Piao L, Fang YH, Cadete VJJ, Wietholt C, Urboniene D, Toth PT, Marsboom G, Zhang HJ, Haber I, Rehman J, Lopaschuk GD, Archer SL. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: Resuscitating the hibernating right ventricle. J Mol Med 2010;88:47– 60. 11. Piao L, Fang Y-H, Parikh K, Ryan JJ, Toth PT, Archer SL. Cardiac glutaminolysis: A maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. J Mol Med S.L. Archer, Department of Medicine, Queen’s University, Etherington Hall, Kingston, ON K7L 3N6, Canada; 2013;91:1185–1197. 12. Talati MH, Brittain EL, Fessel JP, Penner N, Atkinson J, Funke M, Grueter C, Jerome WG, Freeman M, Newman JH, West J, Hemnes AR. Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle. Am J Respir Crit Care Med United States; 2016;194:719–728.